Test Name
EGFR Mutation Analysis
Test Code
M EGFR
Synonyms
ERBB1
Associations
NSCLC
CPT Codes
81235
Turnaround Time
10 days
Specimen Requirements
Formalin Fixed Paraffin Embedded tissue block 3 slides (3-5 uM) per marker on adhesion glass NOTE: Include a surgical pathology report with the sample if sending a block and/or slides 5.0 mL (min. 3.0 mL) whole blood EDTA, Sodium Heparin or ACD 3.0 mL (min. 1.0 mL) bone marrow EDTA, Sodium Heparin or ACD
Specimen Stability
Indefinite at ambient temperature (18-25°C) Whole blood and Bone Marrow stable at 18-25°C for 72 hours or 4°C for up to 7 days
Storage & Handling
Ship ambient. Protect from extreme temperature with an ice pack. Separate ice pack from specimen
Causes for Rejections
Improper specimen labeling; Insufficient sample volume; Clotted specimen; Specimen older than 7 days
Description
This sequencing panel is useful in determining eligibility for tyrosine kinase inhibitor (TKI) therapy in patients with non-small cell lung cancer (NSCLC). The EGFR mutation is present in 10-15% of lung adenocarcinomas, and predicts response to drugs such
References
- Passaro A, Gori B, de Marinis F. (2013) Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-lung 3 and LUX-Lung 6 phase III trials. J Thorac Dis 5(4):383-384
- Cappuzzo F, Finocchiaro G, Metro G, et al. (2006)Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol 58:31-45
- Paez JG, Janne PA, Lee JC, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500
- Sequist LV, Joshi VA, Janne PA, et al. (2007) Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 12:90-8
- Ji H, Li D, Chen L, et al.(2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.Cancer Cell.9:485-95
